Backlash Over Acting FDA Head’s Past Links to Planned Parenthood

The acting leader of the Food and Drug Administration, appointed by President Trump, is facing criticism from segments of the pro-life community. Following the resignation of former FDA Commissioner Marty McCulley, Kyle Diamantas, the deputy commissioner for food, has stepped into the role. Some have raised concerns about his previous association with Planned Parenthood.

Lila Rose, the founder of Live Action, pointed out that Diamantas had been “listed in court records as an attorney for the Planned Parenthood System of Greater Orlando.” She expressed her concerns on social media, stating, “We cannot allow someone representing Planned Parenthood to oversee regulations regarding mifepristone, the deadly abortion drug that has killed millions of babies.” Rose further emphasized the need for a strong pro-life candidate to take over.

Meanwhile, Trump advisor Alex Bruesewitz defended Diamantas against Rose’s claims, suggesting that crucial context was missing from her statements. He specified that Diamantas was a junior associate assigned to a related case but withdrew due to personal beliefs, asserting that he is committed to pro-life principles.

The FDA has yet to comment on the situation. According to reports, Diamantas previously worked as a senior associate at Baker Donelson, where he was involved in family planning litigation. During his time there, he was noted to have had a limited role, having opted out based on his personal beliefs. A source close to Diamantas stated that he donates regularly to pro-life organizations.

Kristan Hawkins, president of Students for Life of America, commented on the political climate within the FDA. “This is why our team did not call for Dr. McCulley’s resignation—I know the FDA is full of pro-abortion leftists,” she mentioned. Hawkins insisted that the new commissioner must show unwavering commitment to protecting both children and their mothers.

Jenny Bradley Richter, chairman of the March for Life Education and Defense Fund, shared her initial impressions of Diamantas, suggesting his outreach to pro-life leaders shortly after assuming his position was a positive sign. She expressed optimism regarding the FDA’s future decisions on mifepristone safety research.

Recent calls for stricter controls on abortion drugs have emerged from anti-abortion groups and certain Republican lawmakers. Senator Bill Cassidy of Louisiana remarked that McCulley’s resignation represented broader issues observed within the administration, emphasizing the need for an FDA nominee who prioritizes the sanctity of life.